NCT04811898View on ClinicalTrials.gov

A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 14, 2019

Primary Completion Date

December 29, 2021

Study Completion Date

December 29, 2021

Conditions

Multiple Myeloma, RefractoryHepatocarcinomaAdvanced Solid Tumor

Interventions

BIOLOGICAL

LNA-i-miR-221

LNA-i-miR-221, IV daily infusion on days 1-4 followed by 24 days washout (1 cycle lasting 28 days)

Trial Locations (1)

88100

Center for Phase I Clinical Studies in Medical Oncology and Oncohematology - Translational Medical Oncology Unit, AOU MaterDomini and Magna Graecia University, Catanzaro

All Listed Sponsors

collaborator

Associazione Italiana per la Ricerca sul Cancro

OTHER

lead

Azienda Ospedaliera Universitaria Mater Domini, Catanzaro

OTHER

NCT04811898 - A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment | Biotech Hunter | Biotech Hunter